LFG
CUE icon

Larson Financial Group’s Cue Biopharma CUE Stock Holding History

Larson Financial Group’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-47
Closed -$1.53K – 3102
2024
Q4 		$1.53K Hold
47
– – ﹤0.01% 1940
2024
Q3 		$1.06K Buy
+47
New +$1.02K ﹤0.01% 1974

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Larson Financial Group's CUE Position: Q1 2025 in Review

Larson Financial Group sold out of Cue Biopharma (CUE) in Q1 2025, closing a stake of 47 shares — an estimated $1.53K sold.

Larson Financial Group first reported a position in CUE in Q3 2024 and held it in 2 quarters. The position peaked at $1.53K in Q4 2024. 49 funds tracked by Wall St. Rank hold CUE as of Q1 2025.

  • Larson Financial Group reported no remaining Cue Biopharma position as of Q1 2025 after selling out during the quarter.
  • Larson Financial Group sold 47 Cue Biopharma shares in Q1 2025, an estimated $1.53K.
  • Larson Financial Group first reported a position in Cue Biopharma in Q3 2024 and held it in 2 quarters.
  • Larson Financial Group's Cue Biopharma position peaked at $1.53K in Q4 2024.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2025.

Based on Larson Financial Group's 13F filing for Q1 2025, filed 2 May 2025.